<DOC>
	<DOCNO>NCT02143219</DOCNO>
	<brief_summary>Metastatic pancreatic carcinoma represent 5th cause cancer death France ( # 8000 per year ) . The median age diagnosis 69 74 male female respectively . When 5-Fluorouracile use single agent limit efficacy 20 year , onset gemcitabine 1995 lead moderate increase median survival ( 4.41 5.65 month ) overall survival 1 year ( 2 versus 18 % ) . Recently , phase II follow phase-III study , French collaborative group demonstrate benefit `` FOLFIRINOX `` regimen versus gemcitabine alone , term median survival ( 11.1 versus 6.8 month ) , progression-free survival ( 6.4 versus 3.3 month ) response rate ( 31.6 versus 9.4 % ) . Although hematologic ( neutropenia ) GI toxicity observe , FOLFIRINOX acceptable new standard regimen majority patient age 70 good Performans Status . To reduce toxicity FOLFIRINOX elderly patient ( &gt; 70 yo ) , pharmacogenetic monitoring 5-FU Irinotecan key metabolism enzyme ( DPD UGTA1 ) may easily perform . The methodology study use Bryant &amp; Day statistical method , allow consider simultaneously principal objective , response rate ( efficacy ) tolerance ( preservation autonomy daily living , Katz index ) : design particularly fitting study elderly patient represent half pancreatic carcinoma population .</brief_summary>
	<brief_title>Efficacy Tolerance Evaluation FOLFIRINOX Dose Adjusted Elderly Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>METHODOLOGY : Phase II study , open , multicentric MAIN OBJECTIVE : The main objective simultaneous evaluation objective rate answer toxicity ( ) protocol FOLFIRINOX administer dos adapt patient 70 year old . SECONDARY OBJECTIVE : - Efficiency evaluation ; - Tolerance evaluation ; - Quality Life ( QoL ) clinical profit . STATISTICAL ANALYSIS : An analysis two stage plan , accord method Bryant Day risk ÃŸ 5 % reject wrongly effective treatment acceptable toxicity risk a=10 % accept wrongly rather effective toxic treatment . The study consider successful : - obtain least 11 tumoral answer - maxi 30 patient 72 loss autonomy ( decrease ADL ) . - All patient receive least injection eligible evaluation toxicity - The evaluation efficiency make 3 cure least unless early termination scanner anticipate . - All toxicity increase accord criterion toxicity NCI-CTC v4.0 . - The evaluation tumoral answer ( CR , PR SD ) make accord criterion RECIST-v1.1 .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Histologically proven ductal pancreatic carcinoma Metastatic disease Firstline treatment : No previous chemotherapy metastatic stage adjuvant treatment relapse ( secondary metastatic ) permit , provide administer 6 month ) Age 70 yo Normal DPD enzyme level partial defect ( exclude total defect ) Adequate bone marrow reserve : indicate : neutrophil &gt; 1500/mm3 , platelet &gt; 100,000/ mm3 , Hb &gt; 10.0g/dL . Adequate Renal function indicate : MDRD creatinine clearance &gt; 50ml/min . Adequate hepatic function indicate : serum bilirubin &lt; 1.5 time upper limit normal , AST ALT &lt; 2.5 time upper limit normal , &lt; 5 time upper limit normal liver metastasis present . Written informed consent must obtain prior protocolspecific procedure perform Patient affiliate social security category Other ductal pancreatic carcinoma : namely endocrin tumor , acinar cell carcinoma , cystadenocarcinoma adenocarcinoma ampulla vater Nonmetastatic locally advance pancreatic adenocarcinoma Complete DPD deficiency History Cardiac failure symptomatic coronary artery disease Autonomy Daily Living score Katz &lt; 4 Prior treatment FOLFIRINOX ( adjuvant ) Major comorbidity likely obstacle treatment Active uncontrolled infection HIV chronic B C hepatitis Uncontrolled diabetes mellitus Prior peripheral neuropathy , grade &gt; 2 Inflammatory bowel disease localize colon rectum ; bowel obstruction severe uncontrolled diarrhea Previous concomitant malignancy effectively treat carcinoma situ cervix nonmelanoma skin cancer Hereditary fructose intolerance Persons deprive liberty guardianship Any social , geographical psychological condition would compromise ability fully comply trial procedure treatment</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pancreatic metastatic cancer</keyword>
	<keyword>FOLFIRINOX</keyword>
	<keyword>toxicity</keyword>
	<keyword>efficacy</keyword>
</DOC>